Abstract:Abstract Background Immunocompromised children and adults are at increased risk for severe disease and death following varicella zoster virus infection. Varicella zoster immune globulin (human) (VARIZIG) is recommended for post-exposure prophylaxis to prevent or attenuate varicella infection in high-risk individuals. Methods An open-label, expanded-access program provided VARIZIG to high-risk individuals exposed to varicella or herpes zoster. Immunocompromised participants were stratified by type of immunocompromising condition (“oncologic immunodeficiency”, “primary immunodeficiency”, “solid organ transplant” [SOT], “hematopoietic cell transplant” [HCT], and “other”). Patient characteristics, type of exposure and varicella outcome, and safety data were assessed. Results This analysis included 40 adults (primary [ n = 6] or oncologic [ n = 10] immunodeficiencies, history of SOT [ n = 5] or HCT [ n = 6], and other [ n = 13]), and 263 children (primary [ n = 13] or oncologic [ n = 152] immunodeficiencies, history of SOT [ n = 36] or HCT [ n = 17], and other [ n = 45]). Among adults and children, 48% vs 72% were exposed to varicella, 38% vs 16% were exposed to herpes zoster, and 15% vs 12% had an unspecified exposure. Overall incidence of varicella infection in adults after VARIZIG use was 6%; incidence of varicella infection in children after VARIZIG use was 7%. Similar rates were noted in each subgroup. Most cases of varicella were mild, with two children developing > 100 lesions and no cases of varicella-related pneumonia or encephalitis. Varicella-related hospitalizations occurred primarily in children with oncologic immunodeficiencies. One serious adverse event (serum sickness) was considered related to VARIZIG and occurred in a child with oncologic immunodeficiency. There were no varicella- or VARIZIG-related deaths. Conclusions These data indicate that VARIZIG may reduce severity of varicella in immunocompromised children and adults. Trial registration This study was retrospectively registered with the public clinical trial identification NCT00338442 at https://www.clinicaltrials.gov on 20 June 2006.

Fatal varicella due to the vaccine-strain varicella-zoster virus

Serious neurological adverse events in immunocompetent children and adolescents caused by viral reactivation in the years following varicella vaccination

Fatal Disseminated Varicella-Zoster Virus in an Immunocompetent Woman

A fatal case of severe systemic varicella zoster infection in a patient with chronic use of immunosuppressive agents for cutaneous vasculitis

Late-Onset Concurrent Infection of Vaccine Strain VZV and HSV-1 after Varicella Vaccination in a Child with Natural killer T Cell Deficiency

Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection

Varicella pneumonia in a healthy 31-year-old female with no prior varicella immunity and no skin rush: A case report

Varicella-zoster virus post-exposure management and prophylaxis: A review

Case Report: Neonatal Varicella Acquired From Maternal Zoster

Varicella Pneumonia in Immunocompetent Adults: Symptomatic and Asymptomatic Cases

Purpura Fulminans Secondary to Varicella-Zoster Virus Infection

Varicella Vaccine: a Molecular Variant That May Contribute to Attenuation

[An autopsied case of severe varicella zoster virus-associated encephalomyelitis under immunosuppressant therapy]

Atypical hemolytic uremic syndrome triggered by varicella infection

Efficacy of varicella (VZV) vaccination: an update for the clinician

Variable Clinical Courses of Varicella Zoster Virus Infection–related or Vaccination-related Bone Marrow Failure

Seroprevalence of varicella-zoster virus as measured by fluorescent antibody to membrane antigen assay and glycoprotein enzyme-linked immunosorbent assay more than 10 years after initiation of a universal vaccination program: An observational study

Fatal Hyperacute Liver Failure due to Varicella Zoster Virus Immediately After Living‐Donor Liver Transplantation: A Case Report and Review of the Literature

Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program

Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs